Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Payables (2019 - 2025)

BridgeBio Pharma's Payables history spans 7 years, with the latest figure at $36.2 million for Q4 2025.

  • For Q4 2025, Payables rose 276.67% year-over-year to $36.2 million; the TTM value through Dec 2025 reached $36.2 million, up 276.67%, while the annual FY2025 figure was $36.2 million, 276.67% up from the prior year.
  • Payables for Q4 2025 was $36.2 million at BridgeBio Pharma, up from $18.7 million in the prior quarter.
  • Across five years, Payables topped out at $36.2 million in Q4 2025 and bottomed at $3.9 million in Q2 2023.
  • The 5-year median for Payables is $11.1 million (2022), against an average of $13.7 million.
  • The largest annual shift saw Payables tumbled 60.62% in 2022 before it surged 482.17% in 2025.
  • A 5-year view of Payables shows it stood at $11.9 million in 2021, then fell by 2.74% to $11.6 million in 2022, then dropped by 7.81% to $10.7 million in 2023, then fell by 9.73% to $9.6 million in 2024, then skyrocketed by 276.67% to $36.2 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Payables are $36.2 million (Q4 2025), $18.7 million (Q3 2025), and $26.1 million (Q2 2025).